EE180 Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.564
https://www.valueinhealthjournal.com/article/S1098-3015(25)03121-3/fulltext
Title :
EE180 Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03121-3&doi=10.1016/j.jval.2025.09.564
First page :
Section Title :
Open access? :
No
Section Order :
10158